Parkinson’s Disease:
Where Our Approach
Proved Itself
Our first discovery put the decision engine to the test. By analyzing national health data and scientific literature, AIICAS identified several drugs and biological signals potentially linked to reduced risk of Parkinson’s disease — developed with access to expertise at the University of Bergen. Parkinson’s is where we started. It won’t be where we stop.
An urgent unmet need, and a powerful first test for our approach
Parkinson’s is one of the fastest-growing neurological conditions, affecting a large and rising number of people as populations age. Yet the experience for patients has changed remarkably little.
Despite decades of research, current treatments mainly manage symptoms — there is still no cure, and no approved therapy that slows the progression of the disease itself. Patients, families, and clinicians are waiting for better answers.
That made Parkinson’s a compelling first test for our approach: a serious unmet need, combined with a deep body of existing medical and neuroscience research — exactly the kind of complex problem our decision engine is built to make sense of.
Why we started with Parkinson’s
A growing patient population
More people live with Parkinson’s every year as populations age — and they need better options.
A significant unmet clinical need
No disease-modifying treatment exists today — current therapies manage symptoms only, leaving a critical gap.
A rich research base to learn from
Decades of neuroscience and medical research create a deep pool of knowledge for AI-assisted analysis.
Proven, trusted medicines to build on
Many existing medicines with relevant biological mechanisms can be studied for new potential.
What our research has uncovered
Instead of starting from a single hypothesis, AIICAS let large health datasets, biological knowledge, and artificial intelligence work together — surfacing patterns that are difficult for people to detect alone.
This work pointed to biological mechanisms that a growing number of researchers believe are central to neurodegenerative disease: energy metabolism, inflammation, stress response, and mitochondrial function. The signals were then explored in the laboratory using zebrafish models.
The next step is to identify biological subgroups of Parkinson’s disease, and use that understanding to develop better, more targeted treatment strategies.
Biological mechanisms in focus
Specific medicine candidates remain confidential pending ongoing research and patent procedures.
Why this work matters for patients
Our goal is simple: to help the research community move toward treatments that change the course of the disease — not only its symptoms.
Toward earlier understanding
Identifying biological subgroups so that the right patients can be recognised sooner.
Toward more precise treatment
Understanding mechanisms so therapies can be matched to the people most likely to benefit.
Built on what’s already trusted
Drawing on medicines and knowledge the medical world already relies on, rather than starting from zero.
Interested in the Parkinson’s application?
We’re actively seeking clinical partners and research institutions to advance our Parkinson’s work.